Aptevo Therapeutics Inc. filed a prospectus supplement with the Securities and Exchange Commission on October 30, 2026, to update its existing sales agreement. The filing relates to the offer and sale of the company’s common stock, with an aggregate offering price of up to $2,309,834. The shares are being sold under an At The Market Offering Agreement dated April 28, 2025, with Roth Capital Partners, LLC, acting as sales agent.
The prospectus supplement amends and supplements previous filings, including the Original Prospectus and subsequent supplements dated April 29, 2025, May 22, 2025, and June 20, 2025. The offering is registered pursuant to an effective registration statement on Form S-3 (File No. 333-284969).
As of the date of the current filing, Aptevo has issued and sold 303,157 shares of common stock pursuant to the Sales Agreement and the prior prospectus supplements. These sales have generated aggregate gross sale proceeds of $11.8 million.
Paul Hastings LLP, the company’s counsel, provided a legal opinion regarding the shares. A copy of this opinion, including the firm's consent, is attached as Exhibit 5.1 to the filing.
